10-K: NovelStem International Corp. Reports Significant Losses and Impairment in 2024 10-K Filing

NovelStem International Corp.'s 2024 10-K filing reveals substantial net losses, an impairment of its NewStem investment, and ongoing concerns about its ability to continue as a going concern.

Summary

• NovelStem International Corp., a holding company with interests in NewStem Ltd. and NetCo Partners, reported a net loss of approximately $3.23 million for the year ended December 31, 2024, compared to a net loss of $4.19 million in 2023.
• The company's principal assets are a 31% equity interest in NewStem and a 50% equity interest in NetCo.
• NewStem, an Israeli biotech company, ceased operations and began liquidation in October 2024 due to its inability to raise funds, leading to a $1.63 million impairment loss for NovelStem.
• NovelStem's ability to continue as a going concern is dependent on improving profitability, receiving continued financial support from shareholders, and Yissum's ability to successfully commercialize the License.
• The company's current liabilities exceeded current assets by approximately $5.27 million as of December 31, 2024.
• NovelStem depends entirely on earnings and cash from its investments in NewStem and the NetCo joint venture.
• The company is in final negotiations to sell its interest in NetCo to its joint venture partner in exchange for the settlement of related debt.
• NovelStem identified a material weakness in its internal control over financial reporting as of December 31, 2024.
• The company has borrowed funds from directors, a shareholder, and unrelated parties to fund operations and NewStem.
• NovelStem has not paid cash dividends since 2018 and does not expect to pay any in the foreseeable future.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant losses, impairment of a major investment, concerns about going concern status, and a material weakness in internal controls. While there are potential positives like the sale of NetCo, the overall tone is pessimistic.

Positives

• The company is in final negotiations to sell its interest in NetCo to its joint venture partner in exchange for the settlement of related debt, which could improve its financial position.
• NovelStem retains a financial interest in any future monetization of the NewStem technology, offering potential future revenue.

Negatives

• NovelStem reported a significant net loss of approximately $3.23 million for the year ended December 31, 2024.
• The company recorded an impairment loss of approximately $1.63 million related to its investment in NewStem, which ceased operations and began liquidation.
• NovelStem's current liabilities exceeded current assets by approximately $5.27 million as of December 31, 2024.
• The company identified a material weakness in its internal control over financial reporting as of December 31, 2024.
• The company depends entirely on earnings and cash from its investments in NewStem and the NetCo joint venture, making it vulnerable to the performance of these investments.
• The company has not paid cash dividends since 2018 and does not expect to pay any in the foreseeable future, which may deter some investors.

Risks

• NovelStem's ability to continue as a going concern is dependent on improving profitability, receiving continued financial support from shareholders, and Yissum's ability to successfully commercialize the License.
• The company's investments in NewStem and NetCo are illiquid and have limited liquidity rights.
• The company depends on its executive officers and consultants, and the loss of their services could harm the company.
• Rapid technological change could cause products to become obsolete.
• The value of the company's investment in NetCo and its ability to receive distributions may be affected by disputes between the company and C.P. Group.
• The company may be deemed an investment company, which could impose burdensome compliance requirements.
• There is a very limited trading market for the company's common stock, and investors are not assured of the opportunity to sell their stock.

Future Outlook

NovelStem's future depends on additional financing, fundraising, and the monetization of assets related to equity method investments, particularly the sale of NetCo and the potential re-licensing or monetization of NewStem's technology by Yissum.

Management Comments

• Management continues to focus on strengthening the Company's internal controls within the parameters of what can be done with limited resources.
• Management plans with regard to these matters include the potential sale of our interest in NetCo to settle our liability related to the litigation funding agreement and additional financing and fundraising until our interest in NewStems technology is profitable.

Industry Context

The biotech industry is characterized by high risk and uncertainty, particularly for development-stage companies like NewStem. The success of such companies depends heavily on their ability to secure funding, achieve regulatory approvals, and successfully commercialize their technologies. The media and publishing industries are also highly competitive, with success dependent on creating and marketing hit products.

Comparison to Industry Standards

• Given NovelStem's holding company structure and reliance on investments, comparing it directly to operating companies in the biotech or media sectors is challenging.
• However, the company's financial performance can be benchmarked against other microcap companies with similar investment strategies and risk profiles.
• The impairment of the NewStem investment highlights the risks associated with early-stage biotech ventures, where clinical trial failures, regulatory hurdles, and funding challenges are common.
• The ongoing arbitration with NetCo's joint venture partner underscores the complexities of managing partnerships and intellectual property rights in the media industry.

Legal Proceedings

• The Company was the claimant in an arbitration proceeding against their 50 % partner in NetCo.
• The arbitrator ruled against the Company on certain key issues of the arbitration and in the Companys favor on two key issues of the arbitration.

Related Party Transactions

• The Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a shareholder and member of the Board, to borrow up to an aggregate of $600,000 for working capital needs.
• On May 5, 2023, the Company entered into a long term note payable with a shareholder for $300,000 in financing.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial difficulties and the potential for further losses.
• Employees and consultants may be affected by cost-cutting measures or changes in the company's operations.
• The liquidation of NewStem impacts its employees and stakeholders.
• Creditors face increased risk of non-payment due to the company's financial distress.

Next Steps

• The company is in the process of selling its interest in NetCo to its joint venture partner.
• The company needs to secure additional financing to continue operations.
• Yissum may re-license or monetize the NewStem technology.
• Management will continue to attempt to build the necessary capabilities and infrastructure to implement corrective action to strengthen the Companys internal controls.

Key Dates

Keywords

NovelStem International Corp, NewStem, NetCo, financial results, 10-K, impairment, liquidation, going concern, litigation funding, internal control, biotech, holding company